Methods of treating diabetes by blocking VEGF-mediated activity

Details for Australian Patent Application No. 2004226417 (hide)

Owner Regeneron Pharmaceuticals, Inc.

Inventors Sleeman, Mark W.; Wiegand, Stanley J.

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-B-2004226417

PCT Pub. Number WO2004/087206

Priority 60/458,790 28.03.03 US

Filing date 26 March 2004

Wipo publication date 14 October 2004

Acceptance publication date 22 January 2009

International Classifications

A61K 38/17 (2006.01) Medicinal preparations containing peptides - from animals

A61P 3/10 (2006.01) Drugs for disorders of the metabolism

C07K 14/71 (2006.01) Peptides having more than 20 amino acids

Event Publications

1 September 2005 PCT application entered the National Phase

  PCT publication WO2004/087206 Priority application(s): WO2004/087206

15 January 2009 Amendment Made

  The nature of the amendment is: Amend the invention title to read Methods of treating diabetes by blocking VEGF-mediated activity

22 January 2009 Application Accepted

  Published as AU-B-2004226417

21 May 2009 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004226421-Use of FGF18 protein, target proteins and their respective encoding nucleotide sequences to induce cartilage formation

2004226403-Treatment of aspergillus infections with thymosin alpha 1